Provided by Tiger Trade Technology Pte. Ltd.

Atossa Genetics

2.27
+0.320016.41%
Post-market: 2.26-0.0100-0.44%18:01 EDT
Volume:113.03K
Turnover:242.08K
Market Cap:22.64M
PE:-0.52
High:2.30
Open:1.96
Low:1.96
Close:1.95
52wk High:19.35
52wk Low:1.70
Shares:9.97M
Float Shares:9.76M
Volume Ratio:1.35
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3427
EPS(LYR):-4.0377
ROE:-89.23%
ROA:-50.69%
PB:0.84
PE(LYR):-0.56

Loading ...

US Research Roundup-Amrize, Dexcom, Lennar

Reuters
·
Yesterday

Atossa Therapeutics : Ascendiant Capital Markets Raises Target Price to $25 from $24

THOMSON REUTERS
·
Yesterday

Atossa Therapeutics Plans Stapled CVR Issuance Tied to Potential FDA Priority Review Voucher Proceeds

Reuters
·
Sep 29

Atossa Therapeutics - Shareholders to Receive One CVR Per Atos Share as of Record Date

THOMSON REUTERS
·
Sep 29

Atossa Therapeutics - Expects to File CVR Agreement with SEC Once Executed

THOMSON REUTERS
·
Sep 29

Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher

THOMSON REUTERS
·
Sep 29

Atossa Therapeutics - Cvrs Entitle Holders to 25% of Net Proceeds, Capped at $50 Mln

THOMSON REUTERS
·
Sep 29

Atossa Therapeutics CEO Steven Quay Joins ARDD 2026 Panel on Clinical Trials, Regulatory Pathways for Aging Diseases

Reuters
·
Sep 24

Atossa Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 10

Atossa Therapeutics Inc Expected to Post a Loss of $1.08 a Share - Earnings Preview

Reuters
·
Aug 07

Atossa Therapeutics Q2 Operating Income USD -8.7 Million

THOMSON REUTERS
·
Aug 07

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
Aug 07

Atossa Therapeutics Q2 Net Loss Widens to $18.1 Million; Reports no Revenue

Reuters
·
Aug 07

Atossa Therapeutics sees opportunities for (Z)-endoxifen beyond breast cancer

TIPRANKS
·
Jul 31

Atossa Therapeutics’ (Z)-endoxifen compounds show anti-breast cancer action

TIPRANKS
·
Jul 28

Atossa Says Novel Endoxifen-related Compounds Show Potent Preclinical Activity in ER-positive Breast Cancer Models

Reuters
·
Jul 28

Atossa Therapeutics Announces AACR Poster Presentation on (z)-endoxifen in Mccune-albright Syndrome

Reuters
·
Jul 21

Atossa Therapeutics Initiated at Buy by Rodman & Renshaw

Dow Jones
·
Jul 08

Atossa Therapeutics initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
Jul 07

Atossa Therapeutics closes registered direct offering raising USD 4.5 million upfront

Reuters
·
Jun 13